San Mateo, CA
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.
epibiologics.comThese are collections EpiBiologics is a part of. Click on the collection name to view similar companies.
Series A
$23,000,000
Series A
$73,050,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on EpiBiologics.